Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system - Summary - MDSpire

Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system

  • By

  • Keyuan Du

  • Chenglong Duan

  • Jiaqi Zhang

  • Jianing Zhang

  • Jinsui Du

  • Yi Pan

  • Zhihao Liu

  • Chenrong Zhang

  • Yuhan Zhang

  • Yibin Zhang

  • Xuan Zhang

  • Zhongxia Sheng

  • Bin Wang

  • Yu Ren

  • Lizhe Zhu

  • June 10, 2026

  • 0 min

Share

Objective:

To compare ILD reporting associations among antineoplastic agents used in breast, ovarian, and prostate cancers and provide clinical context from published literature regarding the significance of ILD.

Approach:
    Key Findings:
    • Trastuzumab deruxtecan (T-DXd) showed the highest adjusted reporting association for ILD according to the study's analysis.
    • Darolutamide and fulvestrant also exhibited elevated ILD reporting associations.
    • Older age and lower body weight were independently associated with ILD reporting.
    • Death-recorded ILD reports had a shorter median time-to-onset compared to non-death-recorded reports in certain weight subgroups.
    • Literature review identified 85 publications with 98 case-level records supporting FAERS findings.
    Interpretation:

    ILD reporting associations vary across antineoplastic agents for sex hormone-sensitive solid tumors.

    Limitations:
    • Findings are hypothesis-generating.
    • Study relies on FAERS data, which may have reporting biases.
    Conclusion:

    The study highlights the variability of ILD reporting associations across antineoplastic agents.

Original Source(s)

Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system

  • by Keyuan Du, Chenglong Duan, Jiaqi Zhang, Jianing Zhang, Jinsui Du, Yi Pan, Zhihao Liu, Chenrong Zhang, Yuhan Zhang, Yibin Zhang, Xuan Zhang, Zhongxia Sheng, Bin Wang, Yu Ren, Lizhe Zhu

  • June 10, 2026

Related Content

Glandular tissue–based versus anatomical landmark–based CTV delineation in postoperative breast cancer radiotherapy: a dosimetric comparison

Global research trends of TCM-based nonpharmacologic interventions in breast cancer supportive care: a bibliometric analysis (2000–2025)

What the Biggest ASCO Cancer Research Updates Could Mean for Patients

Each year, the American Society of Clinical Oncology Annual Meeting brings together cancer specialists from around the world to share the research most likely to shape the next chapter of cancer care. This year’s major updates point to several important themes: more precise treatment, smarter use of surgery and chemotherapy, new approaches for difficult-to-treat cancers and a growing recognition that supportive care, including exercise, can be part of cancer treatment planning.

  • by

  • June 8, 2026

  • 10 min